Compare LSBK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | MNOV |
|---|---|---|
| Founded | 1891 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 66.9M |
| IPO Year | 2025 | 2004 |
| Metric | LSBK | MNOV |
|---|---|---|
| Price | $15.25 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 11.6K | ★ 56.5K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.65 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $11.50 | $1.13 |
| 52 Week High | $16.22 | $1.96 |
| Indicator | LSBK | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 46.32 |
| Support Level | $14.57 | $1.21 |
| Resistance Level | $15.23 | $1.43 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 69.79 | 24.25 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.